MarketPulse

NDA

10 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aquestive Therapeutics Faces Class Action Over Anaphylm FDA Approval Claims

Class action lawsuit filed against $AQST alleging securities fraud over false FDA timeline statements and concealed safety risks for Anaphylm drug.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aquestive Therapeutics Faces Securities Fraud Lawsuit Over FDA Approval Claims

Class action lawsuit filed against $AQST alleging executives made false statements about Anaphylm FDA approval timeline and concealed human factors risks.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aquestive Therapeutics Hit by Securities Fraud Class Action Over FDA Approval Claims

Aquestive Therapeutics faces class action lawsuit alleging securities fraud over false FDA approval statements and concealed anaphylaxis product risks.
AQSTSLNOGOSSsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Corcept Therapeutics Faces Securities Fraud Lawsuit Over Misleading FDA Claims

Law firm Levi & Korsinsky filed class action suit against $CORT alleging fraud regarding relacorilant FDA approval prospects between October 2024 and December 2025.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Corcept Therapeutics Faces Class Action Over Relacorilant Clinical Trial Claims

Class action filed against $CORP alleging securities fraud over misleading statements about relacorilant clinical trials and FDA regulatory prospects.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Corcept Faces Securities Fraud Lawsuit Over Relacorilant Trial Misstatements

Class action lawsuit filed against Corcept Therapeutics alleging securities fraud over misleading statements about relacorilant clinical trials and FDA approval prospects.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aquestive Therapeutics Hit With Securities Fraud Suit Over Anaphylm FDA Timeline Claims

Class action lawsuit filed against Aquestive Therapeutics alleging securities fraud related to Anaphylm FDA approval timeline and undisclosed human factors risks.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Corcept Therapeutics Faces Securities Fraud Class Action Over Relacorilant FDA Claims

Class action lawsuit filed against $CORP alleging false statements about relacorilant clinical trial strength and FDA approval prospects. Investors from Oct 2024-Dec 2025 urged to participate.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aquestive Therapeutics Faces Securities Fraud Suit Over FDA Approval Claims

Class action lawsuit filed against $AQST alleging misleading statements about FDA approval timeline for Anaphylm and concealed human factors risks.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Corcept Therapeutics Hit With Securities Fraud Class Action Over Relacorilant Claims

Class action lawsuit filed against Corcept Therapeutics for allegedly making false claims about relacorilant drug's clinical strength while concealing FDA regulatory concerns.
CORTsecurities fraudclass action lawsuit